Evidence map›Paper›PMID 41206840›Full record

ArticleNeurology and therapy2026

Novel Finding of Retinal Aneurysmal Alterations in Patients Undergoing Fingolimod Therapy for Multiple Sclerosis.

Feliciana Menna, Lucilla Barbano, Carmen Dell'Aquila, Mattia D'Andrea, Vincenzo Parisi, Lucia Ziccardi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Feliciana MennaDepartment of Medical-Surgical Sciences and Biotechnologies, U.O.C. Ophthalmology, Sapienza University of Rome, Via Firenze 1, 04019, Terracina, Italy. feliciana.menna@gmail.com.ORCID http://orcid.org/0000-0002-4347-6573
Lucilla BarbanoClinical and Research Center of Neurophthalmology and Genetic and Rare Diseases of the Eye, IRCCS-Fondazione Bietti, 00198, Rome, Italy.
Carmen Dell'AquilaClinical and Research Center of Neurophthalmology and Genetic and Rare Diseases of the Eye, IRCCS-Fondazione Bietti, 00198, Rome, Italy.
Mattia D'AndreaDepartment of Sense Organs, Faculty of Medicine and Dentistry, Sapienza University of Rome, 00161, Rome, Italy.
Vincenzo ParisiClinical and Research Center of Neurophthalmology and Genetic and Rare Diseases of the Eye, IRCCS-Fondazione Bietti, 00198, Rome, Italy.
Lucia ZiccardiClinical and Research Center of Neurophthalmology and Genetic and Rare Diseases of the Eye, IRCCS-Fondazione Bietti, 00198, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFingolimod (Gilenya

methodsCase series of five eyes of five patients with retinal aneurysmal alterations and in therapy with fingolimod for multiple sclerosis. Multimodal imaging scans and medical records of patients on fingolimod therapy were reviewed. Outcome measures included best-corrected visual acuity (BCVA), central subfield thickness (CST) on spectral-domain optical coherence tomography (SD-OCT), presence of retinal aneurysmal alterations and analysis of their change in appearance over time using OCT angiography (OCTA).

resultsFindings indicate a possible association between fingolimod therapy and unilateral retinal aneurysmal changes in certain patients. The proposed mechanisms include endothelial retinal dysfunction, altered retinal vascular permeability and immune modulation effects. The clinical significance of these changes remains uncertain, necessitating further investigation.

conclusionsFingolimod may contribute to unilateral retinal aneurysmal vascular changes in a subset of patients. Clinicians should remain vigilant for potential retinal vascular complications, and further research is needed to clarify the underlying mechanisms, the evolution and the long-term risks associated with fingolimod therapy. Notably, in the reported cases, the retinal aneurysmal alterations showed regression following the discontinuation of fingolimod, suggesting a potential reversibility of these changes upon cessation of treatment.

Indexed as

Cerebrovascular diseaseFingolimodGilenyaMultiple sclerosisRetinal aneurysmal alterationsRetinal vascular complicationsSphingosine-1-phosphate receptors

Identifiers

PMID41206840
PMCPMC12804496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.